Voiceonics Ltd
Intended clinical use.

The TTS100 (AAC) device is intended to provide an effective reduction in the effect of the symptoms of moderate to severe expressive communication disabilities, notably Dysarthria, Developmental Verbal Dyspraxia, Apraxia of speech and Dysphasia (Aphasia).

These symptoms may occur in association with the following conditions;

ALS (amyotrophic lateral sclerosis or Lou Gehrig’s Disease);

Cerebral Palsy;

Multiple Sclerosis;

Parkinson’s disease;

Brain stem stroke;

Huntington’s disease;

Guillain-Barre Syndrome;

Traumatic brain injury;

Severe developmental communication impairments (e.g. Autism and other developmental disabilities).

The TTS100 (AAC) device can only be operated via the key-board. As such the patient must have sufficient hand movement and coordination to operate a key-board.

Return to TTS100 AAC device